IP Library › Granted Patent US 6,916,848
Granted Patent B2
US 6,916,848 · App. 10/684,730 · Granted Jul 12, 2005

Compounds for the treatment of metabolic disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,916,848
App. No.
10/684,730
Granted
Jul 12, 2005
Kind
B2
Abstract

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Claims (6)

1. A compound of the formula:

wherein

R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms;

or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.

2. The compound or salt of claim 1 , wherein R 1 is hydrogen or ethyl.

3. The compound or salt of claim 2 , wherein the compound is 4-(2,6-difluorophenyl)-4-oxobutyric acid.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 055056/0891 →
SECURITY AGREEMENT Recorded Sep 18, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0227 →
SECURITY AGREEMENT Recorded Aug 16, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0875 →